Evidence map›Paper›PMID 40373263›Full record

Trial reportJCO oncology practice2026

Low-Intensity Vibration to Reduce Symptoms and Improve Physical Functioning in Cancer Survivors With Chemotherapy-Induced Peripheral Neuropathy: A Pilot Randomized Trial.

Stephanie M Krasnow, Clinton T Rubin, Eric J Roeland, Fay B Horak, Sydnee A Stoyles, Nathan F Dieckmann, Kendra N Braun, Kerri M Winters-Stone

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Supportive care: Comparing exercise interventions for upper extremity polyneuropathy induced by chemo- or immunotherapy - VISCIPH B.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Stephanie M KrasnowDivision of Oncological Sciences, Knight Cancer Institute, School of Medicine, Oregon Health & Science University, Portland, OR.ORCID 0000-0003-0507-4669
Clinton T RubinStony Brook University, Stony Brook, NY.ORCID 0000-0003-0909-7999
Eric J RoelandDivision of Oncological Sciences, Knight Cancer Institute, School of Medicine, Oregon Health & Science University, Portland, OR.ORCID 0000-0002-3674-3573
Fay B HorakDepartment of Neurology, School of Medicine, Oregon Health & Science University, Portland, OR.
Sydnee A StoylesSchool of Nursing, Oregon Health & Science University, Portland, OR.ORCID 0000-0001-6755-0902
Nathan F DieckmannSchool of Nursing, Oregon Health & Science University, Portland, OR.ORCID 0000-0001-5061-9889
Kendra N BraunDivision of Oncological Sciences, Knight Cancer Institute, School of Medicine, Oregon Health & Science University, Portland, OR.
Kerri M Winters-StoneDivision of Oncological Sciences, Knight Cancer Institute, School of Medicine, Oregon Health & Science University, Portland, OR.ORCID 0000-0003-1706-8020

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
Patterns and predictors of symptoms, falls, and functioning across treatment and recovery in patients treated with neurotoxic chemotherapy for cancerR01CA248059 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI WINTERS-STONE, KERRI M · 2020 to 2024
$3.1M
NCI NIH HHS P30 CA069533NCI NIH HHS R01 CA248059
6 · The paper itself

Abstract

purposeChemotherapy-induced peripheral neuropathy (CIPN) can have deleterious effects on mobility and quality of life in people with cancer. Vibration therapy shows promise as a CIPN intervention but is understudied. We investigated the feasibility and preliminary efficacy of low-intensity vibration (LIV) in cancer survivors with CIPN.

methodsWe conducted a pilot randomized controlled trial in adult cancer survivors with persistent CIPN symptoms. Participants were randomly assigned to twice-daily LIV sessions (10 min/session; 30 Hz, 0.4 g) for 12 weeks or usual care (UC). We assessed feasibility by accrual, retention, adherence, and adverse event (AE) reporting. We evaluated preliminary efficacy by changes in patient-reported CIPN symptoms (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity), pain (Brief Pain Inventory), fatigue (Patient-Reported Outcome Measurement Information System Fatigue), and physical functioning (Late-Life Function and Disability Instrument) and objectively measured physical functioning (chair stand time, gait speed), stability (postural sway), and mobility (Timed-Up-and-Go). Linear regression models were used to generate effect size estimates (Cohen's d).

resultsWe accrued 95% of our target sample (n = 38, mean age: 62.6 ± 9.9 years, 89% female, median time since chemotherapy completion: 18 [6-39] months), with 20 participants randomly assigned to LIV and 18 to UC. Trial retention was 97% and mean adherence to LIV was 77% ± 18%. There were no serious AEs. Compared with UC, LIV participants reported greater improvements in sensory neuropathy symptoms (LIV, +1.4 ± 3.3 points; UC, +0.2 ± 2.8 points; Cohen's d = 0.45) and basic lower extremity function (LIV, +5.3 ± 8.5 points; UC, -0.7 ± 9.2 points; Cohen's d = 0.80), with moderate-to-large effect sizes for changes in stability, mobility, and gait (Cohen's d = 0.60-0.66).

conclusionLIV is safe, feasible, and shows preliminary efficacy for CIPN symptom relief and improving physical functioning in cancer survivors with CIPN.

Indexed as

Antineoplastic AgentsCancer SurvivorsNeoplasmsPeripheral Nervous System DiseasesVibrationAdultAgedFemaleHumansMaleMiddle AgedPilot ProjectsQuality of LifeAntineoplastic Agents

Identifiers

PMID40373263
PMCPMC12353142

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.